西藏藥業(600211.SH):合作方斯微生物mRNA新冠疫苗獲批臨試
格隆匯1月5日丨西藏藥業(600211.SH)宣佈,公司於2021年1月4日獲悉,斯微生物收到了國家藥品監督管理局核准簽發的mRNA新型冠狀病毒肺炎疫苗的《藥物臨牀試驗批件》。
針對此次新型冠狀病毒肺炎,斯微生物於2020年1月緊急啟動新冠mRNA疫苗研發項目,並完成了所有候選疫苗的藥效學研究。目前,該疫苗在國內已獲得臨牀批件,將按計劃開展臨牀試驗;海外相關工作尚未啟動,海外申報、註冊、審評、產品上市需遵照當地的法律法規要求。
按照協議安排,公司已於協議簽署後支付了預付款3500萬人民幣(含税);此次獲得《藥物臨牀試驗批件》後,需向斯微生物支付相應里程碑款3500萬人民幣(含税)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.